La-Beck NM - Search Results

1

Antibody-drug conjugates: an evolving approach for melanoma treatment.

Anderson TS, Wooster AL, La-Beck NM, Saha D, Lowe DB. Anderson TS, et al. Among authors: la beck nm. Melanoma Res. 2021 Feb 1;31(1):1-17. doi: 10.1097/CMR.0000000000000702. Melanoma Res. 2021. PMID: 33165241 Review.

2

Immune Checkpoint Inhibitors: New Insights and Current Place in Cancer Therapy.

La-Beck NM, Jean GW, Huynh C, Alzghari SK, Lowe DB. La-Beck NM, et al. Pharmacotherapy. 2015 Oct;35(10):963-76. doi: 10.1002/phar.1643. Pharmacotherapy. 2015. PMID: 26497482 Review.

3

New insights and evolving role of pegylated liposomal doxorubicin in cancer therapy.

Gabizon AA, Patil Y, La-Beck NM. Gabizon AA, et al. Drug Resist Updat. 2016 Nov;29:90-106. doi: 10.1016/j.drup.2016.10.003. Epub 2016 Oct 29. Drug Resist Updat. 2016. PMID: 27912846 Review.

4

Optimizing Patient Outcomes with PD-1/PD-L1 Immune Checkpoint Inhibitors for the First-Line Treatment of Advanced Non-Small Cell Lung Cancer.

La-Beck NM, Nguyen DT, Le AD, Alzghari SK, Trinh ST. La-Beck NM, et al. Pharmacotherapy. 2020 Mar;40(3):239-255. doi: 10.1002/phar.2364. Epub 2020 Jan 29. Pharmacotherapy. 2020. PMID: 31930528 Review.

5

Repurposing amino-bisphosphonates by liposome formulation for a new role in cancer treatment.

La-Beck NM, Liu X, Shmeeda H, Shudde C, Gabizon AA. La-Beck NM, et al. Semin Cancer Biol. 2021 Jan;68:175-185. doi: 10.1016/j.semcancer.2019.12.001. Epub 2019 Dec 23. Semin Cancer Biol. 2021. PMID: 31874280 Review.

6

Translational considerations in nanomedicine: The oncology perspective.

Gabizon AA, de Rosales RTM, La-Beck NM. Gabizon AA, et al. Among authors: la beck nm. Adv Drug Deliv Rev. 2020;158:140-157. doi: 10.1016/j.addr.2020.05.012. Epub 2020 Jun 9. Adv Drug Deliv Rev. 2020. PMID: 32526450 Review.

7

Nanoparticle-Induced Complement Activation: Implications for Cancer Nanomedicine.

La-Beck NM, Islam MR, Markiewski MM. La-Beck NM, et al. Front Immunol. 2021 Jan 8;11:603039. doi: 10.3389/fimmu.2020.603039. eCollection 2020. Front Immunol. 2021. PMID: 33488603 Free PMC article. Review.

8

Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.

Islam MR, Patel J, Back PI, Shmeeda H, Adamsky K, Yang H, Alvarez C, Gabizon AA, La-Beck NM. Islam MR, et al. Among authors: la beck nm. Nanotheranostics. 2022 Sep 1;6(4):451-464. doi: 10.7150/ntno.75045. eCollection 2022. Nanotheranostics. 2022. PMID: 36105861 Free PMC article.

9

Pegylated Liposomal Alendronate Biodistribution, Immune Modulation, and Tumor Growth Inhibition in a Murine Melanoma Model.

Islam MR, Patel J, Back PI, Shmeeda H, Kallem RR, Shudde C, Markiewski M, Putnam WC, Gabizon AA, La-Beck NM. Islam MR, et al. Among authors: la beck nm. Biomolecules. 2023 Aug 26;13(9):1309. doi: 10.3390/biom13091309. Biomolecules. 2023. PMID: 37759709 Free PMC article.

10

Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin.

Petersen GH, Alzghari SK, Chee W, Sankari SS, La-Beck NM. Petersen GH, et al. J Control Release. 2016 Jun 28;232:255-64. doi: 10.1016/j.jconrel.2016.04.028. Epub 2016 Apr 22. J Control Release. 2016. PMID: 27108612

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

26 results

Search Page